Fresenius Medical Care (NYSE: FMS) reported Q2 EPS of EUR0.91, EUR0.41 better than the analyst estimate of EUR0.50. Revenue for the quarter came in at EUR4.79 billion versus the consensus estimate of EUR5.82 billion.

Outlook 2025 confirmed

Fresenius Medical Care confirms its outlook for fiscal 2025 and expects revenue growth to be positive to a low-single digit percent rate compared to prior year. The Company expects operating income excluding special items to grow by a high-teens to high-twenties percent rate compared to prior year.

The expected growth rates for 2025 are at constant currency, excluding special items in operating income. The 2024 basis for the revenue outlook is EUR 19,336 million and for the operating income outlook is EUR 1,797 million.

For earnings history and earnings-related data on Fresenius Medical Care (FMS) click here.